_id
690daefdccc777a4e85d0ace
Ticker
ANIK
Name
Anika Therapeutics Inc
Exchange
NASDAQ
Address
32 Wiggins Avenue, Bedford, MA, United States, 01730
Country
USA
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Currency
USD
Website
https://www.anika.com
Description
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide short-and long-term pain relief. The company's joint preservation and restoration product family comprises orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions. In addition, the company offers non-orthopedic products comprising HA-based products for Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier for use after abdominal-pelvic surgeries; and Hyalomatrix for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Last Close
9.49
Volume
109186
Current Price
9.56
Change
0.7376185458377269
Last Updated
2025-11-28T12:14:44.895Z
Image
data:image/webp;base64,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
Ipo Date
1993-04-29T00:00:00.000Z
Market Cap
141039520
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.9995250000000001
Sentiment Sources
4
Rating
4.6667
Target Price
16
Strong Buy
2
Buy
1
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
27817000
Cost Of Revenue
12233000
Gross Profit
15584000
Operating Expenses
18817000
Operating Income
-3233000
Interest Expense
1211000
Pretax Income
-2236000
Net Income
-2329000
Eps
-0.16217533597938863
Dividends Per Share
-
Shares Outstanding
14421219
Income Tax Expense
939000
EBITDA
-833000
Operating Margin
-11.622389186468707
Total Other Income Expense Net
997000
Cash
57990000
Short Term Investments
-
Receivables
22187000
Inventories
16283999
Total Current Assets
101590000
Property Plant Equipment
64910000
Total Assets
189437000
Payables
4732000
Short Term Debt
1725000
Long Term Debt
-
Total Liabilities
42632000
Equity
146805000
Depreciation
1403000
Change In Working Capital
4410000
Cash From Operations
6870000
Capital Expenditures
1887000
Cash From Investing
-1732000
Cash From Financing
-13000
Net Change In Cash
4823000
PE
-
PB
0.9351940329007868
ROE
-1.586458226899629
ROA
-1.2294324762322038
FCF
4983000
Fcf Percent
0.17913506129345363
Piotroski FScore
2
Health Score
51
Deep Value Investing Score
7.5
Defensive Investing Score
7
Dividend Investing Score
3
Economic Moat Investing Score
5.8
Garp Investing Score
4
Growth Investing Score
2.5
Momentum Investing Score
2.5
Net Net Investing Score
4.5
Quality Investing Score
4.5
Value Investing Score
5.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
27817000
Quarters > 0 > income Statement > cost Of Revenue
12233000
Quarters > 0 > income Statement > gross Profit
15584000
Quarters > 0 > income Statement > operating Expenses
18817000
Quarters > 0 > income Statement > operating Income
-3233000
Quarters > 0 > income Statement > interest Expense
1211000
Quarters > 0 > income Statement > pretax Income
-2236000
Quarters > 0 > income Statement > net Income
-2329000
Quarters > 0 > income Statement > eps
-0.16217533597938863
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
14361000
Quarters > 0 > income Statement > income Tax Expense
939000
Quarters > 0 > income Statement > EBITDA
-833000
Quarters > 0 > income Statement > operating Margin
-11.622389186468707
Quarters > 0 > income Statement > total Other Income Expense Net
997000
Quarters > 0 > balance Sheet > cash
57990000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
22187000
Quarters > 0 > balance Sheet > inventories
16283999
Quarters > 0 > balance Sheet > total Current Assets
101590000
Quarters > 0 > balance Sheet > property Plant Equipment
64910000
Quarters > 0 > balance Sheet > total Assets
189437000
Quarters > 0 > balance Sheet > payables
4732000
Quarters > 0 > balance Sheet > short Term Debt
1725000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
42632000
Quarters > 0 > balance Sheet > equity
146805000
Quarters > 0 > cash Flow > net Income
-2329000
Quarters > 0 > cash Flow > depreciation
1403000
Quarters > 0 > cash Flow > change In Working Capital
4410000
Quarters > 0 > cash Flow > cash From Operations
6870000
Quarters > 0 > cash Flow > capital Expenditures
1887000
Quarters > 0 > cash Flow > cash From Investing
-1732000
Quarters > 0 > cash Flow > cash From Financing
-13000
Quarters > 0 > cash Flow > net Change In Cash
4823000
Quarters > 0 > ratios > PE
-0.16217533597938863
Quarters > 0 > ratios > PB
0.9351940329007868
Quarters > 0 > ratios > ROE
-1.586458226899629
Quarters > 0 > ratios > ROA
-1.2294324762322038
Quarters > 0 > ratios > FCF
4983000
Quarters > 0 > ratios > Piotroski FScore
2
Quarters > 0 > ratios > fcf Percent
0.17913506129345363
Quarters > 0 > health Score
51
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
28219000
Quarters > 1 > income Statement > cost Of Revenue
13856000
Quarters > 1 > income Statement > gross Profit
14363000
Quarters > 1 > income Statement > operating Expenses
18543000
Quarters > 1 > income Statement > operating Income
-4180000
Quarters > 1 > income Statement > interest Expense
629000
Quarters > 1 > income Statement > pretax Income
-3966000
Quarters > 1 > income Statement > net Income
-3970000
Quarters > 1 > income Statement > eps
-0.27702184076477565
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
14331000
Quarters > 1 > income Statement > income Tax Expense
681000
Quarters > 1 > income Statement > EBITDA
-2764000
Quarters > 1 > income Statement > operating Margin
-14.812714837520819
Quarters > 1 > income Statement > total Other Income Expense Net
214000
Quarters > 1 > balance Sheet > cash
53167000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
23955000
Quarters > 1 > balance Sheet > inventories
16922000
Quarters > 1 > balance Sheet > total Current Assets
99317000
Quarters > 1 > balance Sheet > property Plant Equipment
65805000
Quarters > 1 > balance Sheet > total Assets
187682000
Quarters > 1 > balance Sheet > payables
4771000
Quarters > 1 > balance Sheet > short Term Debt
1815000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
40010000
Quarters > 1 > balance Sheet > equity
147672000
Quarters > 1 > cash Flow > net Income
-3970000
Quarters > 1 > cash Flow > depreciation
1416000
Quarters > 1 > cash Flow > change In Working Capital
-3833000
Quarters > 1 > cash Flow > cash From Operations
-189000
Quarters > 1 > cash Flow > capital Expenditures
1467000
Quarters > 1 > cash Flow > cash From Investing
-539000
Quarters > 1 > cash Flow > cash From Financing
179000
Quarters > 1 > cash Flow > net Change In Cash
-204000
Quarters > 1 > ratios > PE
-0.27702184076477565
Quarters > 1 > ratios > PB
0.9277612546725175
Quarters > 1 > ratios > ROE
-2.6883904870252993
Quarters > 1 > ratios > ROA
-2.115280101448194
Quarters > 1 > ratios > FCF
-1656000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-0.05868386548070449
Quarters > 1 > health Score
34
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
26168000
Quarters > 2 > income Statement > cost Of Revenue
11487000
Quarters > 2 > income Statement > gross Profit
14681000
Quarters > 2 > income Statement > operating Expenses
18965000
Quarters > 2 > income Statement > operating Income
-4284000
Quarters > 2 > income Statement > interest Expense
415000
Quarters > 2 > income Statement > pretax Income
-3869000
Quarters > 2 > income Statement > net Income
-4873000
Quarters > 2 > income Statement > eps
-0.3408407358187032
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
14297000
Quarters > 2 > income Statement > income Tax Expense
89000
Quarters > 2 > income Statement > EBITDA
-2692000
Quarters > 2 > income Statement > operating Margin
-16.371140324059922
Quarters > 2 > income Statement > total Other Income Expense Net
415000
Quarters > 2 > balance Sheet > cash
53371000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
21987000
Quarters > 2 > balance Sheet > inventories
21336000
Quarters > 2 > balance Sheet > total Current Assets
102509000
Quarters > 2 > balance Sheet > property Plant Equipment
65641000
Quarters > 2 > balance Sheet > total Assets
190605000
Quarters > 2 > balance Sheet > payables
5277000
Quarters > 2 > balance Sheet > short Term Debt
1874000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
42208000
Quarters > 2 > balance Sheet > equity
148397000
Quarters > 2 > cash Flow > net Income
-4873000
Quarters > 2 > cash Flow > depreciation
1592000
Quarters > 2 > cash Flow > change In Working Capital
-269000
Quarters > 2 > cash Flow > cash From Operations
-130000
Quarters > 2 > cash Flow > capital Expenditures
2824000
Quarters > 2 > cash Flow > cash From Investing
1672000
Quarters > 2 > cash Flow > cash From Financing
-5438000
Quarters > 2 > cash Flow > net Change In Cash
-3788000
Quarters > 2 > ratios > PE
-0.3408407358187032
Quarters > 2 > ratios > PB
0.9210382959224245
Quarters > 2 > ratios > ROE
-3.2837591056422974
Quarters > 2 > ratios > ROA
-2.5565961018860994
Quarters > 2 > ratios > FCF
-2954000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-0.11288596759400794
Quarters > 2 > health Score
34
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
-1290000
Quarters > 3 > income Statement > cost Of Revenue
-23855000
Quarters > 3 > income Statement > gross Profit
22565000
Quarters > 3 > income Statement > operating Expenses
-5253000
Quarters > 3 > income Statement > operating Income
27818000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
28562000
Quarters > 3 > income Statement > net Income
-21865000
Quarters > 3 > income Statement > eps
-1.485293118674003
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
14721000
Quarters > 3 > income Statement > income Tax Expense
2870000
Quarters > 3 > income Statement > EBITDA
26529000
Quarters > 3 > income Statement > operating Margin
-2156.434108527132
Quarters > 3 > income Statement > total Other Income Expense Net
744000
Quarters > 3 > balance Sheet > cash
55629000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
23594000
Quarters > 3 > balance Sheet > inventories
23809000
Quarters > 3 > balance Sheet > total Current Assets
113652000
Quarters > 3 > balance Sheet > property Plant Equipment
64679000
Quarters > 3 > balance Sheet > total Assets
202740000
Quarters > 3 > balance Sheet > payables
5617000
Quarters > 3 > balance Sheet > short Term Debt
1918000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
48751000
Quarters > 3 > balance Sheet > equity
153989000
Quarters > 3 > cash Flow > net Income
-21865000
Quarters > 3 > cash Flow > depreciation
1812000
Quarters > 3 > cash Flow > change In Working Capital
-2363000
Quarters > 3 > cash Flow > cash From Operations
1582000
Quarters > 3 > cash Flow > capital Expenditures
1307000
Quarters > 3 > cash Flow > cash From Investing
-1307000
Quarters > 3 > cash Flow > cash From Financing
-5354000
Quarters > 3 > cash Flow > net Change In Cash
-5209000
Quarters > 3 > ratios > PE
-1.485293118674003
Quarters > 3 > ratios > PB
0.9139143705069843
Quarters > 3 > ratios > ROE
-14.199066167063881
Quarters > 3 > ratios > ROA
-10.78474893952846
Quarters > 3 > ratios > FCF
275000
Quarters > 3 > ratios > Piotroski FScore
2
Quarters > 3 > ratios > fcf Percent
-0.2131782945736434
Quarters > 3 > health Score
35
Valuation > metrics > PE
-0.16217533597938863
Valuation > metrics > PB
0.9351940329007868
Valuation > final Score
70
Valuation > verdict
6.5% Undervalued
Profitability > metrics > ROE
-1.586458226899629
Profitability > metrics > ROA
-2.2925484791810216
Profitability > metrics > Net Margin
-0.08372577919976992
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.29039882837778
Risk > metrics > Interest Coverage
-2.6696944673823286
Risk > final Score
49
Risk > verdict
High
Liquidity > metrics > Current Ratio
15.733312683908936
Liquidity > metrics > Quick Ratio
13.21139863713799
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
70
Prev Valuations > 1
70
Prev Valuations > 2
70
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
30
Prev Risks > 0
33
Prev Risks > 1
19
Prev Risks > 2
100
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-14T00:13:43.543Z
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide short-and long-term pain relief. The company's joint preservation and restoration product family comprises orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions. In addition, the company offers non-orthopedic products comprising HA-based products for Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier for use after abdominal-pelvic surgeries; and Hyalomatrix for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Stock Price
$ 0.00
0% increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AJobs Data: Why Pimco 15 Year U.S. stock is a strong buy call - July 2025 Price Swings & High Accuracy Trade Alerts moha.gov.vn
Read more →Trend Dashboard Flags Anik Industries Limited As Potential Swing Trade - Fundamental Stock Analysis & You’ll Thank Yourself in 6 Months earlytimes.in
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$16
Analyst Picks
Strong Buy
2
Buy
1
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 73.54% of the total shares of Anika Therapeutics Inc
1.
Trigran Investments Inc(14.1247%)
since
2025/06/30
2.
BlackRock Inc(10.5998%)
since
2025/06/30
3.
Caligan Partners LP(9.9537%)
since
2025/06/30
4.
Vanguard Group Inc(5.4062%)
since
2025/06/30
5.
Dimensional Fund Advisors, Inc.(4.3215%)
since
2025/06/30
6.
Opaleye Management Inc(4.0837%)
since
2025/06/30
7.
BOOTHBAY FUND MANAGEMENT, LLC(3.6725%)
since
2025/06/30
8.
Renaissance Technologies Corp(3.6566%)
since
2025/06/30
9.
Alta Fundamental Advisers LLC(3.1554%)
since
2025/06/30
10.
Capital Management Corp(2.8356%)
since
2025/06/30
11.
State Street Corp(2.2497%)
since
2025/06/30
12.
Geode Capital Management, LLC(2.2278%)
since
2025/06/30
13.
Stonepine Capital Management Llc(1.3219%)
since
2025/06/30
14.
Millennium Management LLC(0.9271%)
since
2025/06/30
15.
Charles Schwab Investment Management Inc(0.9228%)
since
2025/06/30
16.
D. E. Shaw & Co LP(0.8606%)
since
2025/06/30
17.
Envestnet Asset Management Inc(0.8419%)
since
2025/06/30
18.
Jacobs Levy Equity Management, Inc.(0.8277%)
since
2025/06/30
19.
Northern Trust Corp(0.795%)
since
2025/06/30
20.
Morgan Stanley - Brokerage Accounts(0.7517%)
since
2025/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.